Skip to content

Nutritional Assessment in Patient of Mucopolysaccharide

Nutritional Assessment of Patient of Mucopolysaccharide

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07136896
Enrollment
40
Registered
2025-08-22
Start date
2025-08-16
Completion date
2026-08-30
Last updated
2025-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malnutrition (Calorie), Mucopolysaccharidosis (MPS), Undernutrition

Keywords

Caloric deficiency, Pediatric nutrition

Brief summary

Nutritional assessment in patients of Mucopolysaccharide

Detailed description

The mucopolysaccharidoses (MPS) are lysosomal diseases caused by the deficiency of enzymes required for the stepwise breakdown of glycosaminoglycans (GAGs), previously known as mucopolysaccharides, Fragments of partially degraded GAGs accumulate in the lysosomes, resulting in cellular dysfunction and clinical abnormalities The main GAG chains are degraded by 11 lysosomal hydrolases enzymes gives rise to the progressive accumulation of GAGs in most tissues and organ systems, as well as in urine Individuals with MPS disorders share many similar symptoms such as multiple organ involvement, distinctive coarse facial features, and abnormalities of the skeleton especially joint problems. Additional findings include short stature, heart abnormalities, breathing irregularities, hepatosplenomegaly and neurological abnormalities. The severity of the different MPS disorders varies greatly among affected individuals, even among those with the same type of MPS and even among individuals of the same family. In most cases of MPS, affected infants appear normal at birth and symptoms become apparent around the age of one or two, however, in MPS VII, approximately 40% of pregnancies with an affected baby are complicated by a condition called non-immune hydrops fetalis. Mild forms of these disorders may not become apparent until childhood or adolescence. In most cases, the mucopolysaccharidoses are chronic, progressive disorders and, depending upon the type of MPS and severity, affected individuals may experience a decline in physical and mental function, sometimes resulting in life-threatening complications. Nutritional assessment in MPS focuses on identifying and addressing potential deficiencies and challenges related to the disease's impact on growth, development, and feeding. This involves evaluating dietary intake, assessing growth parameters, and monitoring for specific nutrient deficiencies, particularly those impacting bone health and overall metabolic function The dietetic treatment of MPS does not only aim to correct diarrhea and constipation but also help in the consistency of the dysphagia treatment probable adequacy in vitamin (B1, B2, and B3) levels since they are largely spread in the food. These vitamins may participate in energetic metabolism, in redox reactions. In this regard, niacin plays a critical role in nucleic acids, fatty acids and cholesterol synthesis, DNA repair, and steroid hormones production.

Interventions

OTHERNutritional Assessment Protocol

Participants will undergo a comprehensive nutritional assessment, including anthropometric measurements (weight, height, BMI, skinfold thickness), dietary intake evaluation through 24-hour recall, and bioelectrical impedance analysis to assess body composition. Relevant biochemical parameters will also be measured to evaluate nutritional status

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Participants will be assigned to one of two parallel groups: children with mucopolysaccharidosis (MPS) and age-matched healthy controls. Both groups will undergo the same nutritional assessment protocol for comparison.

Eligibility

Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

Confirmed diagnosis of mucopolysaccharidosis (any subtype) by enzymatic assay or genetic testing Age between 1 and 18 years Stable clinical condition at time of enrollment Informed consent obtained from parent/guardian, and assent from child when applicable -

Exclusion criteria

Presence of other chronic conditions affecting growth or nutrition (e.g., untreated endocrine disorders, severe cardiac failure unrelated to MPS) Acute illness or hospitalization within the last 2 weeks prior to assessment Patients who received nutritional supplementation or dietary intervention within 3 months prior to enrollment that could affect baseline nutritional assessment Refusal or inability to comply with study assessments \-

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of malnutrition among patients with mucopolysaccharidosis1 yearThe percentage of patients diagnosed with malnutrition, as determined using the World Health Organization (WHO) growth standards. Malnutrition will be defined based on weight-for-age, height-for-age, and weight-for-height Z-scores below -2 standard deviations. Data will be collected at baseline and expressed as a percentage of the study population.
severity of malnutrition among patients with mucopolysaccharidosisby WHO growth standards Z-scores (weight-for-age, height-for-age, weight-for-height)At baseline (upon enrollment)Severity of malnutrition will be assessed using the Gomez classification based on weight-for-age percentage of the median for the reference population. Categories include: mild (75-89%), moderate (60-74%), and severe (\<60%). Data will be expressed as the proportion of patients in each severity category at baseline
Prevalence and severity of malnutrition among patients with mucopolysaccharidosisAt baseline (upon enrollment)The proportion of patients diagnosed with mucopolysaccharidosis (MPS) who present with any degree of malnutrition, categorized as mild, moderate, or severe according to WHO growth standards. Severity will be determined using anthropometric indices (weight-for-age, height-for-age, BMI-for-age z-scores, and mid-upper arm circumference) and compared across disease subtypes and age groups.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026